Elanco Animal Health Inc. ELAN Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Elanco Animal Health Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The official record: Elanco Animal Health Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Elanco Animal Health Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Elanco Animal Health Inc.'s cash & equivalents?
- Elanco Animal Health Inc. (ELAN) reported cash & equivalents of $428M in Q1 2026.
- How has Elanco Animal Health Inc.'s cash & equivalents changed year-over-year?
- Elanco Animal Health Inc.'s cash & equivalents decreased by 12.1% year-over-year, from $487M to $428M.
- What is the long-term trend for Elanco Animal Health Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Elanco Animal Health Inc.'s cash & equivalents has grown at a 1.5% compound annual growth rate (CAGR), from $506M to $545M.
- What does cash & equivalents mean?
- The total value of cash and highly liquid investments that can be accessed immediately.
- How do you interpret cash & equivalents?
- An increase suggests strong liquidity and financial flexibility, while a decrease may indicate heavy capital expenditure, debt repayment, or operational cash burn.
- How does cash & equivalents compare across companies?
- Standard across all industries; peers in pharmaceuticals typically maintain significant cash balances for R&D and M&A.